Cypre is a biotechnology company dedicated to working with therapeutic innovators to overcome drug resistance for cancer patients. Used by top-10 pharmaceuticals, a multitude of biotechs, and leading academic centers, our 3D in vitro tumor microenvironment models aim to reduce and eventually replace animal tumor models in predicting efficacy and MOA outcomes in an accelerated timeline for the next generation of targeted and immunotherapies. At Cypre, we believe the ideal model combines the complexity of human tumor microenvironment (TME) biology, including fibroblasts, immune cells, and ECM density; the predictivity of a wide range of therapeutic classes (e.g. chemotherapy, targeted therapy, immunotherapy); and the throughput for comprehensive and standardized analytics such as high content imaging, cytokines and flow cytometry.